Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin

Hepatology Research

Volumn 42, Issue 3, 2012, Pages 241-247

  Nomura, Hideyuki ^a   Miyagi, Yuugou ^a   Tanimoto, Hironori ^a   Yamashita, Nobuyuki ^a   Oohashi, Seiji ^a   Nishiura, Saburo ^a  

^a Shin Kokura Hospital   (Japan)

Author keywords

Beck Depression Inventory II; Chronic hepatitis C; Depression; Natural interferon ; Pegylated interferon ; Pittsburgh Sleep Quality Index

Indexed keywords

ANTIDEPRESSANT AGENT; BETA INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; BECK DEPRESSION INVENTORY; DEPRESSION; HEALTH SURVEY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84857564729     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00930.x     Document Type: Article

References (19)

1. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol 2009; 44: 338-45.
4. Nomura H, Miyagi Y, Tanimoto H, Ishibashi H. Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. J Viral Hepat 2009; 16: 346-51.
5. Kumada H, Okanoue T, Onji M etal. The Study for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labor and Welfare of Japan: guideline for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
6. Kainuma M, Furusyo N, Kajiwara E etal. Kyushu University Liver Disease Study Group. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.
7. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
8. Chayama K, Hayes CN, Abe H etal. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 2011; 204: 84-93.
9. Scalori A, Pozzi M, Bellia V etal. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005; 37: 102-7.
10. Schaefer M, Schwaiger M, Garkisch AS etal. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42: 793-8.
11. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-11.
12. Asahina Y, Izumi N, Uchihara M etal. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-84.
13. Nomura H, Sou S, Nagahama T, Hayashi J, Kashiwagi S, Ishibashi H. Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C. Hepatol Res 2004; 28: 36-40.
14. Arase Y, Suzuki F, Akuta N etal. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Intern Med 2010; 49: 957-63.
15. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67: 588-97.
16. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatr Res 1998; 28: 193-213.
17. Berg T, von Wagner M, Nasser S etal. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
18. Zeniya M, Yokoyama K, Imamura N etal. Significance of interferon-beta for the treatment of hepatitis C virus infection in hemodialyzed patients. Hepatol Res 2010; 40 (9): 862-9.
19. Arase Y, Suzuki F, Akuta N etal. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Intern Med 2010; 49: 965-70.